India's furniture sector is set for a major boost. New free trade agreements will open up export markets and encourage investment. Domestic...

India is initiating plans for a 6G mobile communication transition. Discussions will focus on developing local technology and fostering res...

India may be adding more trade partners, but its latest FTA report card comes with several red marks. A new study by the Global Trade Resea...

India is planning the second phase of its semiconductor incentive scheme, DLI 2.0. Concerns are rising among domestic startups that allowin...

Indian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...

The new refrigerants called hydrofluoroolefins, or HFOs, are quickly replacing older hydrofluorocarbons, or HFCs, in the USA and Europe as ...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

The US-China AI rivalry has intensified, moving beyond innovation to a battle for talent, IP, and strategic tech. China's blocking of Meta'...

The US accuses China of stealing AI intellectual property, escalating the tech rivalry beyond tariffs. This move, potentially impacting chi...

Tejas Networks reported a significant widening of its net loss to Rs 211.3 crore in Q4 FY26, with revenue plummeting 82.6% year-on-year. De...

India's patent filings reached a historic high of over 1.43 lakh in FY 2025-26, a 30.2% jump. Domestic innovators led this surge, with Tami...

India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...

The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...

Indian patenting system needs to be improved for faster approvals, N N Prasad, Executive Director, WIPO, said here today.

Faced with losses once its blockbusters start losing patents, Big Pharma is now devising strategies to counter the impact.

Pharma giants like Pfizer, Novartis and Merck have seen their market capitalisation erode over the last three years, as sales started to wi...

This one’s a pop out for pharma. Revenues from new product launches in the pharma sector fell 48% to Rs 224.2 crore in ’05.